TipRanks
Go Ultimate55% OFF

JBS (JBSN) AI Stock Analysis

MX:JBSN

JBS

(BMV:JBSN)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Diversified global protein platformJBS's broad beef, poultry, pork and prepared-food portfolio serves retail, foodservice and industrial customers across geographies. That diversification can spread demand exposure, support scale economics and preserve multiple routes to growth as individual protein cycles fluctuate.
Negative Factors
Leverage remains above targetNet leverage above the stated target leaves balance-sheet repair as an ongoing priority. Elevated leverage can restrict capital-allocation flexibility and increase sensitivity to cyclical protein earnings, while the company's planned interest expense of about $1.3 billion adds pressure to cash resources.

JBS (JBSN) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%MX:JBSN+2.55%SPY+11.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
MXN 27.70B
Dividend Yield
9.11%
Average Volume (3M)
5,798
Price to Earnings (P/E)
18.1
Beta (1Y)
0.49
Revenue Growth
299.57%
EPS Growth
-23.32%
Country
Mexico
Employees
283,000
Sector
Consumer Defensive
Sector Strength
62
Industry
Packaged Foods

JBS Business Overview & Revenue Model

Company Description

JBS NV is a food company that engages in the sale of beef, pork, lamb meat and poultry products. It offers its products to supermarkets, club stores, other retail distributors, and foodservice companies. The company was founded on October 9, 2019 and...

JBS Earnings Call Summary

Earnings Call Date:Aug 10, 2026(Q2-2026)|% Change Since:-3.09%|Next Earnings Date:Nov 08, 2026
Earnings Call SentimentNeutral

The call conveyed a mixed but resilient picture: several meaningful operational and strategic positives (record revenue, positive adjusted EBITDA, restored free cash flow, a major JV to accelerate Asia expansion, improved pork margins and progress in U.S. beef operations) were offset by material financial headwinds (a GAAP net loss driven by nonrecurring charges, a YoY EBITDA decline, higher financial expenses and interest costs, elevated capex, and leverage slightly above target). Management emphasized execution, cash generation and disciplined capital allocation while outlining pathways (Mexican border reopening, operational initiatives, JV funding) to improve performance.

Positive Updates

Record Quarterly Revenue
Net sales reached a record $24.0 billion in Q2 2026, reflecting strong top-line performance across the global platform.

Negative Updates

Reported Net Loss and EPS Impacted by Nonrecurring Items
The quarter reported a net loss of $102 million and a negative EPS of $0.10. Excluding nonrecurring items management reported adjusted net income of $218 million and adjusted EPS of $0.20, highlighting material one-off impacts to GAAP results.

Company Guidance

Management’s guidance emphasized cash generation and balance‑sheet repair with a 2026 cash‑flow breakeven EBITDA target of $5.1 billion, capital expenditures of $2.0 billion (down $400 million vs. initial estimates, including ~$159 million expansion CapEx in Q2), working capital expected at negative $350 million in 2026 (a $500 million improvement YoY), and $100 million of legal settlements already realized; other 2026 assumptions include biological assets of $850 million (flat vs. 2025), interest expense of ~$1.3 billion (up $150 million vs. prior plan), leasing expense of $500 million, and an effective tax rate of ~25%. Management also highlighted stronger liquidity (RCF increased from $3.5 billion to $4.2 billion and total cash + RCF ≈ $7.7 billion), an average debt term of 15.3 years at a 5.7% cost, no significant near‑term maturities, 35% of gross debt beyond 2050, and a Q2 free cash flow improvement to +$130 million (vs. -$55 million a year earlier) while net leverage finished Q2 at 3.1x (target 2–3x) with most free cash flow expected in H2.

JBS Risk Analysis

JBS disclosed 49 risk factors in its most recent earnings report. JBS reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

JBS Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

MX:JBSN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SFDSFD69Neutral$7.22B8.0112.99%6.47%-1.57%3.81%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
HRLHRL58Neutral$11.71B33.774.33%5.50%0.73%-54.64%
KHCKHC53Neutral$28.86B-8.51-8.44%6.57%-1.62%36.06%
CPBCPB49Neutral$6.39B15.9810.18%6.63%-4.96%-33.88%
CAGCAG46Neutral$6.96B-3.66-26.28%8.41%-1.80%-323.82%

* Consumer Defensive Sector Average

Performance Comparison

-20%0%20%MX:JBSNCPBCAGHRLKHCSFDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
MX:JBSN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MX:JBSNJbs N.V.235.5011.965.35%
CPBCampbell Soup Company21.42-6.69-23.80%
CAGConagra Brands14.57-1.78-10.89%
HRLHormel Foods Corp21.280.934.56%
KHCKraft Heinz Co24.341.576.89%
SFDSmithfield Foods, Inc.18.34-2.57-12.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.